金属基抗体药物偶联物。作为癌症靶向治疗在其应用中的潜力和挑战。
Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.
机构信息
Department of Chemistry, Brooklyn College, The City University of New York, Brooklyn, NY 11210, USA.
Department of Chemistry, Brooklyn College, The City University of New York, Brooklyn, NY 11210, USA; Biology PhD Program, The Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, USA; Biochemistry PhD Program, The Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, USA; Chemistry PhD Program, The Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, USA; Cancer Biology Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, USA.
出版信息
J Inorg Biochem. 2019 Oct;199:110780. doi: 10.1016/j.jinorgbio.2019.110780. Epub 2019 Jul 18.
Antibody drug conjugates have emerged as a very attractive type of targeted therapy in cancer. They combine the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutics. This review focuses on antibody drug conjugates based on metal-containing cytotoxic payloads. We will also describe antibody drug conjugates (ADCs) in which a metal-based component (mostly metallic nanoparticles) exerts a relevant function in the ADC (for photodynamic or photothermal therapy, as air-plasma-enhancer or chemo-sensitizer, as carrier of other cytotoxic payloads or as an integral part of the linker structure). Challenges and opportunities to increase the translational potential of these ADCs will be discussed.
抗体药物偶联物在癌症的靶向治疗中是一种非常有吸引力的治疗方法。它们将单克隆抗体（mAbs）的抗原靶向特异性与化疗药物的细胞毒性结合在一起。本综述重点介绍了基于含金属细胞毒性有效载荷的抗体药物偶联物。我们还将描述抗体药物偶联物（ADC），其中基于金属的成分（主要是金属纳米颗粒）在 ADC 中发挥相关功能（用于光动力或光热治疗、作为空气等离子体增强剂或化疗增敏剂、作为其他细胞毒性有效载荷的载体或作为连接子结构的组成部分）。将讨论增加这些 ADC 转化潜力的挑战和机遇。
Zotero 插件